Comparison of Short- and Long-term Outcomes Between Robotic and Laparoscopic Hemicolectomy of Right Colon Cancer : A Multicenter Propensity Score Matching Analysis

Not yet recruiting

• Conditions: Robotic Surgical Procedures; Right Colon Tumors; Cancer; Laparoscopic Abdominal Surgery

• Registration Number: NCT07029464
• Lead Sponsor: The First Affiliated Hospital of Nanchang University

Brief Summary

This is a retrospective, multicenter cohort study to compare short- and long-term outcomes between robotic and laparoscopic hemicolectomy of right colon cancer.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-05-26
• Status Verified: 2025-06
• Study Start: 2025-06
• Study First Submitted QC: 2025-06-17
• Last Update Submitted: 2025-06-17
• Study First Posted: 2025-06-19
• Last Update Posted: 2025-06-19
• Primary Completion: 2026-05
• Study Completion: 2027-05

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 4000

Inclusion Criteria

• 1.Underwent radical right hemicolectomy by Da Vinci robotic or laparoscopic surgery 2.Postoperative pathology confirmed right colon adenocarcinoma (pT2-T4aNxM0; including cecal adenocarcinoma, ascending colon adenocarcinoma, hepatic flexure colon adenocarcinoma, and proximal transverse colon adenocarcinoma) 3.Complete clinical data and pathological results available

Exclusion Criteria

• 1.Received neoadjuvant therapy prior to surgery 2.History of other malignancies in the past 5 years (except cured cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin) 3.Distant metastases (e.g., liver, lung) or extensive abdominal/pelvic metastases confirmed by contrast-enhanced CT, PET-CT, or intraoperative exploration 4.Comorbid neurological/psychiatric disorders impairing ability to express informed consent 5.Poor systemic condition with contraindications to general anesthesia 6.Severe obesity (BMI >35 kg/m²) 7.Severe widespread abdominal adhesions precluding safe pneumoperitoneum establishment 8.Emergency surgery due to tumor perforation or obstruction 9.Refusal to provide informed consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
3-year overall survival (OS) rate and 3-year disease-free survival (DFS) rate	（OS）From post-operation until death or the 3-year study endpoint （DFS）From post-operation to tumor recurrence or the 3-year study endpoint

Secondary Outcome Measures

Name	Time	Method
Intraoperative blood loss	Periprocedural
Time to first flatus/bowel movement	Periprocedural
Time to liquid diet initiation	Periprocedural
Time to ambulation	Periprocedural
Postoperative hospital stay duration	Up to 30 days
Postoperative complications	From end of surgery to 30 days postoperatively	Surgery-related adverse events within 30 days, graded via the Clavien-Dindo classification system
Postoperative white blood cell (WBC) count	On postoperative days 1, 3, and 5	Measured on postoperative days 1, 3, and 5
Postoperative C-reactive protein (CRP) level	On postoperative days 1, 3, and 5	Measured on postoperative days 1, 3, and 5
Pain score	On postoperative days 1, 3, and 5	Assessed using the Visual Analog Scale (VAS) on postoperative days 1, 3, and 5
Operative time	Periprocedural